References
- De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61:27–37. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11219548
- McEvoy GK. AHFS drug information 2016. Bethesda, Maryland: American Society of Health-System Pharmacists (ASHP); 2016. Available from: http://www.ovid.com/site/catalog/databases/48.jsp
- Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol. 2013;9(7):911–926.
- Sweetman SC. Martindale: the complete drug reference. 36th. Book & CD-ROM Package. London: Pharmaceutical Press; 2009. Available from: https://www.amazon.com/Martindale-Complete-Reference-CD-ROM-Package/dp/0853698422
- EMC. Sporanox Capsules. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/1513/smpc
- Bennett JE. Antifungal agents. goodman & gilman’s the pharmacological basis of therapeutics. Brunton LL: McGraw-Hill Book Company, New York; 2011. p. 1571–1591.
- Abuhelwa AY, Foster DJ, Mudge S, et al. Population pharmacokinetic modeling of itraconazole and hydroxyl itraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–5696.
- Abuhelwa AY, Mudge S, Hayes D, et al. Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH, and pharmacokinetics. Itraconazole as Model Drug Pharm Res. 2016;33(7):1782–1794.
- Peeters J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91(6):1414–1422.
- Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(Suppl 1):i17–i22.
- Bae SK, Park SJ, Shim EJ, et al. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when co administered with a vitamin C beverage in healthy participants. J Clin Pharmacol. 2011;51(3):444–451.
- Yun HY, Baek MS, Park IS, et al. Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol. 2006;62(12):1033–1039.
- Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol. 1997;52(3):235–237.
- Dollery C. Therapeutic drugs. 3rd ed. Churchill Livingstone. Edinburgh; 1999. Available from: https://www.abebooks.com/servlet/BookDetailsPL?bi=20489195262&searchurl=isbn%3D9780443051487%26sortby%3D17&cm_sp=snippet-_-srp1-_-title3
- Marwaha RK, Maheshwari A. Systemic antifungal therapy in pediatric practice. Indian Pediatr. 1999;36(10):1011–1021.
- Allegra S, Fatiguso G, De Francia S, et al. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Clin Exp Pharmacol Physiol. 2017;44(11):1083–1088.
- Public Assessment Report. Decentralised Procedure Itraconazole 100 mg Capsules. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con046562.pdf.
- Fagiolino P, González N, Vázquez M, et al. Itraconazole bioequivalence revisited: influence of gender on highly variable drugs. The Open Drug Metabol J. 2007;1:7–13.
- Guideline on the investigation of bioequivalence. European Medicines Agency (EMA). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
- Shah VP, Yacobi A, Barr WH, et al. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res. 1996;13(11):1590–1594.
- Medicines and Medical Devices Agency of Serbia (MMDAS). Available from: https://www.alims.gov.rs/eng/.
- Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci. 2012;15(1):73–84.
- Reddy PB, Someswara RK, Kumar S, et al. Sample size estimation for highly variable drug using reference scaled average bioequivalence criteria. Int J Rec Scient Res. 2015;6(7):5040–5045.
- Haidar SH, Makhlouf F, Schuirmann DJ, et al. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J. 2008;10(3):450–454.
- Patni AK, Monif T, Khuroo AH, et al. A comparative bioavailability study of two formulations of itraconazole 100 mg capsule in healthy human Indian subjects under fasting conditions. Clinic Res Regul Aff. 2010;27:128–132.
- Patni AK, Monif T, Khuroo AH, et al. Determination of pharmacokinetics of itraconazole in healthy Indian subjects under fed condition and incurred sample analysis using a validated liquid chromatography tandem mass spectrometric method. Clinic Res Regul Aff. 2012;29:35–40.
- Guideline on Bioanalytical Method Validation. European Medicines Agency (EMA). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
- Shargel L, Wu-Pong S, Yu A. Applied Biopharmaceutics & Pharmacokinetics. 6th. Shargel, Applied Biopharmaceuticals & Pharmacokinetics. New York, NY: McGraw-Hill Companies Inc; 2012. Available from: https://www.amazon.com/Applied-Biopharmaceutics-Pharmacokinetics-Shargel-Biopharmaceuticals/dp/0071375503
- Questions & Answers: Positions on specific questions addressed to the pharmacokinetics working party. European Medicines Agency (EMA). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pdf.
- Leys C, Ley C, Klein O, et al. Detecting outliers: do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol. 2013;49(4):764–766.
- Guideline Clinical Safety Data Management: Definitions AND Standards FOR Expedited Reporting E2A. International Conference on Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human use (ICH). Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
- The use of the WHO-UMC system for standardized case causality assessment. The Uppsala Monitoring Centre. Available from: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf.
- Introductory Guide MedDRA Version 18.0. International Conference on Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human use (ICH). Available from: https://www.meddra.org/sites/default/files/guidance/file/intguide_18_0_english.pdf.
- Wouters OJ, Kanavos PG, McKee M. Comparing generic drug markets in europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95(3):554–601.
- Jakovljevic M, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Exp Rev Pharmacoecon Outcom Res. 2014;14(2):181–194.
- Public Assessment Report. Decentralised Procedure. Lozanoc 50 mg Hard Capsules. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con249676.pdf.
- Public Assessment Report Scientific Discussion. Itraconazol Actavis 100 mg, capsules, hard (itraconazole). Available from: https://db.cbg-meb.nl/Pars/h107049.pdf.
- Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet. 2009;48(11):725–743.
- Guidance for industry bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Department of health and human services food and drug administration Center for Drug Evaluation and Research (CDER). Available from: https://www.fda.gov/downloads/drugs/guidances/ucm377465.pdf.
- Davit BM, Chen ML, Conner DP, et al. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US food and drug administration. AAPS J. 2012;14(4):915–924.
- Midha K, Rawson M, Hubbard J. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005;43(10):485–498.
- Mino Y, Naito T, Watanabe T, et al. Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole. Clin Chim Acta. 2013;415:128–132.
- Dominguez-Gil Hurle A, Sanchez Navarro A, Garcia Sanchez MJ. Therapeutic drug monitoring of itraconazole and relevance of pharmacokinetic interactions. Clin Microbiol Infect. 2006;12(Suppl 7):97–106.